Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 Gross Margin % is 83.63% as of Jun. 2026, which is 0% below its 10-year median of 83.99. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 939 Drug Manufacturers companies, Essex Bio-Technology ranks better than 96.7% on this metric.
The historical rank and industry rank for Essex Bio-Technology's Gross Margin % or its related term are showing as below:
HKSE:01061'
s Gross Margin % Range Over the Past 10 Years
Min: 80.32 Med: 83.99 Max: 90.26
Current: 86.85
During the past 13 years, the highestGross Margin % of Essex Bio-Technology was 90.26%. The lowest was 80.32%. And the median was 83.99%.
HKSE:01061's Gross Margin % is ranked better than 96.7% of 939
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs HKSE:01061: 86.85
Essex Bio-Technology had a gross margin of 83.63% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Essex Bio-Technology was 1.80% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Essex Bio-Technology had a gross margin of 83.63% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Essex Bio-Technology Gross Margin % Related Terms
Essex Bio-Technology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Essex Bio-Technology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Essex Bio-Technology (HKSE:01061) has a Gross Margin % of 83.63% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Essex Bio-Technology and its competitors. This is near median its historical median of 83.99. Over the past decade, Essex Bio-Technology's Gross Margin % has ranged from 80.32 to 90.26. According to the industry distribution chart, Essex Bio-Technology ranks #31 out of 939 companies in the Drug Manufacturers industry, placing it in the top 3.3%.
Is Essex Bio-Technology's Gross Margin % too high?
Essex Bio-Technology's current Gross Margin % of 83.63% is near median its 10-year median of 83.99. Over the past 10 years, this metric has ranged from a low of 80.32 to a high of 90.26. The Drug Manufacturers industry median Gross Margin % is 48.54. Essex Bio-Technology's value of 83.63% is 72.3% above this industry median. Based on the distribution chart, Essex Bio-Technology ranks #31 out of 939 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #31 out of 939 companies for Gross Margin %. This places Essex Bio-Technology in the top 3% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Essex Bio-Technology's value of 83.63% is 72.3% above this benchmark. Historically, Essex Bio-Technology's own Gross Margin % has ranged from 80.32 to 90.26 over the past decade. While the company's 10-year median is 83.99 vs. the industry median of 48.54, Essex Bio-Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current Gross Margin % of 83.63% is 72.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current Gross Margin % is 83.63%, which is near median its own 10-year median of 83.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Gross Margin % is 83.63%, which is near median its 10-year median of 83.99 and 72.3% above the Drug Manufacturers industry median of 48.54. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Gross Margin % is 83.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
Gross Margin %: 83.63% (near median its 10-year median of 83.99)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 72.3% above the Drug Manufacturers median (#31 of 939)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
